New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring most driver gene alterations. Starting from the first generation, research rapidly moved to the development of newer, more selective generations of TKIs...

Full description

Bibliographic Details
Main Authors: Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Ester Del Signore, Pamela Trillo Aliaga, Antonio Passaro, Filippo de Marinis
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
TKI
targeted treatments
lung cancer
resistance
selective pressure
Online Access:https://www.mdpi.com/2072-6694/15/20/5079

Internet

https://www.mdpi.com/2072-6694/15/20/5079

Similar Items